Lucid Diligence Brief: Kailera Therapeutics $600m Series B
Lucid Diligence Brief: Kailera Therapeutics $600m Series B Professional…
Lucid Diligence Brief: Shuttle Pharma x Molecule.ai LOI
Lucid Diligence Brief: Shuttle Pharma x Molecule.ai LOI Professional audiences…
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close Professional…
How we helped an established hemophilia player optimize its market access, pricing and reimbursement strategies in the US and EU5 markets.
The Challenge: How can an established player adapt its market access and…
Managed Entry Agreements: The confidentiality issue
Managed Entry Agreements (MEAs) are contracts between pharmaceutical companies/…
Biosimilars: Enhancing physician uptake in the EU
At the moment, EU physicians seem much more comfortable than their US…
The curious case of biosimilar launches in the US
The Biologics Price Competition and Innovation Act (BPCI Act) of 2009 provided…